StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSE:ATNM – Free Report) from a sell rating to a hold rating in a research report sent to investors on Wednesday. Separately, HC Wainwright ...

Actinium正在推进ATNM-400的研发，预计将从Pluvicto耐药性前列腺癌模型中获得更多数据。该公司更广泛的研发重点包括几个针对实体瘤适应症的临床前项目，利用其拥有的230项与靶向放射疗法和Ac-225制造相关的专利和专利申请组合。

Investing.com — Actinium制药公司（NYSE AMERICAN: ATNM），一家专注于靶向放射治疗的公司，已从Eckert & Ziegler获得了放射性同位素锕-225（Ac-225）的供应，旨在推进其国内外癌症治疗的临床试验。

NEW YORK, NY / / April 3, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ATNM-400, a novel, non-PSMA targeting, first in ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it will be presenting a business update today at ...

Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism.

Law Offices of Howard G. Smith announces an investigation on behalf of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) investors concerning the Company ...

Actinium Pharmaceuticals Inc. has unveiled ATNM-400, a novel non-PSMA-targeting, first-in-class radiotherapy for prostate cancer utilizing the Actinium-225 (Ac-225) radioisotope.

(ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that results from the clinical trial evaluating Actimab-A in combination with the ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth ...

NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ...